Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma

Honda, Yohji; Kimura, Tomoki; Aikata, Hiroshi; Kobayashi, Tomoki; Fukuhara, Toru; Kitajima, Masaki; Nakahara, Takashi; Naeshiro, Noriaki; Ono, Atsushi; Miyaki, Daisuke; Nagaoki, Yuko; Takaki, Shintaro; Hiramatsu, Akira; Ishikawa, M.; Kakizawa, Hideaki; Kenjo, Masahiro; Takahashi, Shoichi; Awai, Kazuo; Nagata, Yasushi; Chayama, Kazuaki

doi:10.1111/jgh.12087

Cited by 97 publications

(81 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The current treatment of HCC involves resection followed by radiation and chemotherapy, thus, there is an urgent need to elucidate the underlying molecular mechanisms of HCC and find new molecular targets for treatment of this disease [2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

miR-411 regulated ITCH expression and promoted cell proliferation in human hepatocellular carcinoma cells

Xia

Zhang

Cao

et al. 2015

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

miR-411 regulated ITCH expression and promoted cell proliferation in human hepatocellular carcinoma cells

Xia

Zhang

Cao

et al. 2015

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

“…At 1 year, local control rates range from 64 to 100%, and OS ranges from 48 to 100% [28,[38][39][40][41][42][43][44][45][46][47][48][49]. These results are particularly impressive given the number of patients included in these studies who had advanced disease and had failed prior therapies.…”

Section: Overviewmentioning

confidence: 59%

“…For example, in a phase I study of SBRT in 31 patients with unresectable HCC at Princess Margaret Cancer Centre, there were no cases of RILD or treatment-related grade ≥4 toxicity, and median survival was 13.4 months [28]. Outcomes are particularly impressive in patients with early stage tumors [38,39,50], with 1-year local control rates of 95-100% and 1-year OS rates of 99-100% seen in two series of SBRT for tumors measuring 1-5 cm [38,39]. SBRT has also been shown to be well tolerated in prospective studies assessing quality-of-life metrics [51].…”

Section: Overviewmentioning

confidence: 99%

Liver-Directed Radiotherapy for Hepatocellular Carcinoma

Keane

Hong

2016

Liver Cancer

View full text Add to dashboard Cite

Background: The incidence of hepatocellular carcinoma (HCC) continues to increase world-wide. Many patients present with advanced disease with extensive local tumor or vascular invasion and are not candidates for traditionally curative therapies such as orthotopic liver transplantation (OLT) or resection. Radiotherapy (RT) was historically limited by its inability to deliver a tumoricidal dose; however, modern RT techniques have prompted renewed interest in the use of liver-directed RT to treat patients with primary hepatic malignancies. Summary: The aim of this review was to discuss the use of external beam RT in the treatment of HCC, with particular focus on the use of stereotactic body radiotherapy (SBRT). We review the intricacies of SBRT treatment planning and delivery. Liver-directed RT involves accurate target identification, precise and reproducible patient immobilization, and assessment of target and organ motion. We also summarize the published data on liver-directed RT, and demonstrate that it is associated with excellent local control and survival rates, particularly in patients who are not candidates for OLT or resection. Key Messages: Modern liver-directed RT is safe and effective for the treatment of HCC, particularly in patients who are not candidates for OLT or resection. Liver-directed RT, including SBRT, depends on accurate target identification, precise and reproducible patient immobilization, and assessment of target and organ motion. Further prospective studies are needed to fully delineate the role of liver-directed RT in the treatment of HCC.

show abstract

“…Local recurrences were significantly reduced and OS improved by combined treatment. Honda et al [18] also recorded a rise in complete responses upon addition of SBRT to TACE in patients with solitary HCC ≤3 cm, and in patients subjected to SBRT after incomplete response to TACE, the survival outcomes registered by Paik et al [19] approached those of complete TACE responders or curative measures. SBRT as adjuvant therapy may well improve the efficacy of TACE, but no clinical data at present suggest that TACE improves the efficacy of SBRT in early-stage HCC.…”

Section: Combination With Other Therapiesmentioning

confidence: 99%

Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting

et al. 2017

View full text Add to dashboard Cite

Background: Stereotactic body radiation therapy (SBRT) is an advanced technique of external beam radiation therapy that delivers large ablative doses of radiation. In the past decade, many cancer centers have adopted SBRT as one mode of radically treating small-sized hepatocellular carcinoma (HCC), based on encouraging clinical outcomes. SBRT thus seems reasonable as first-line treatment of inoperable HCC confined to the liver. However, most of the clinical studies to date have been retrospective in nature, with key issues still under investigation. Summary: The above-mentioned publications were subjected to scrutiny, fueling discussions at the 7th Asia-Pacific Primary Liver Cancer Expert (APPLE 2016) Meeting on various clinical variables, such as indications for SBRT, therapeutic outcomes, treatment-related toxicities, doses prescribed, and specific techniques. The consensus reached should be of interest to all professionals active in the treatment of HCC, especially radiation oncologists. Key Messages: SBRT is a safe and effective therapeutic option for patients with small-sized HCC, offering substantial local control, improved overall survival, and low toxicity.

show abstract

Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma

Abstract: The results indicated that SBRT combined with TACE is a safe and effective modality for locoregional treatment of small solitary primary HCC, and could be potentially a suitable option.

Cited by 97 publications

References 31 publications

miR-411 regulated ITCH expression and promoted cell proliferation in human hepatocellular carcinoma cells

miR-411 regulated ITCH expression and promoted cell proliferation in human hepatocellular carcinoma cells

Liver-Directed Radiotherapy for Hepatocellular Carcinoma

Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting

Contact Info

Product

Resources

About